533 



I understand that recent epidemiological studies that demonstrate statistical asso- 

 ciation are insufficient alone to propel a ban on consumer products or to move their 

 classification as an addictive substance. 



Certainly, before we start to criticize the industry's manufacturing process we 

 should be very certain of the facts. 



Let's leave the decision to use or not to use a tobacco product to the public after 

 we provide them with complete and honest information about the product and it's 

 production. 



I am very concerned about the health of the American people, but my concern also 

 extends to the millions of workers in one of the largest industries in America. We 

 need to be sure of the facts of the tobacco issue before we denigrate an entire indus- 

 try by loose interpretations of biased reports and slanderous remarks made by U.S. 

 Government officials. 



I look forward to hearing what these panels have to say. I have a healthy cyni- 

 cism for all the claims made by the parties on both sides of this matter, and I look 

 forward to getting to the honest facts about these issues. 



I yield back the balance of my time. 



Mr. Waxman. Gentlemen, we welcome you to our hearing today. 

 There is a blue pamphlet at the witness table, that will inform you 

 of the limits on the power of this subcommittee and the extent of 

 your rights during your appearance today. You, I'm sure, are all 

 aware that you are entitled to be represented by counsel, or ad- 

 vised by counsel during your appearance here today. Do you or 

 those of who you have asked to accompany you object to appearing 

 before this subcommittee under oath? 



[No response.] 



Mr. Waxman. If not, I'd like you to rise, and those who will be 

 testifying, as well, with you to rise. Will you raise your right 

 hands? 



[Witnesses sworn.] 



Mr. Waxman. Please consider yourself to be under oath. And 

 we'd like to ask each of you to identify yourself, including those 

 who are accompanying the witnesses, so that we can have that for 

 the record. 



Mr. Campbell. William Campbell, President of Philip Morris 

 U.S.A. I'm accompanied by Harold Burnley, our director of process- 

 ing, and Dr. Kathy Ellis, our director of research. 



Mr. James Johnston. I am Jim Johnston. I'm chairman and 

 CEO of RJ Reynolds Tobacco Company. I am accompanied by Andy 

 Schindler, our head of manufacturing and operations; Carl Leh- 

 man, our head of R and D; and Richard Cooper, our outside counsel 

 and former general counsel of the FDA. 



Mr. Taddeo. My name is Joe Taddeo. I am president of U.S. To- 

 bacco. I'm accompanied by Robert Lawrence, he is our executive 

 vice president of manufacturing and R and D. 



Mr. TISCH. Mr. Chairman, I'm Andrew H. Tisch, chairman and 

 chief executive officer of Lorillard Tobacco Company. With me is 

 Dr. Alexander W. Spears, Lorillard's vice chairman and chief oper- 

 ating office. Dr. Spears has senior responsibility for Lorillard's re- 

 search and production operations. 



Mr. HORRIGAN. Mr. Chairman, I'm Ed Horrigan, chairman and 

 chief executive officer of Liggett Group. Accompan3dng me this 

 morning is Greg Sulin, our vice president of operations. 



Mr. Sandefur. Mr. Chairman, I'm Tommy Sandefur, chairman 

 and chief executive officer of Brown and Williamson Tobacco Com- 

 pany. I'm accompanied by Dr. John Jewell, who is in charge of our 



